LABELS · e2f39a72-c677-4ded-a10c-da739f457180

EPKINLY

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2026-06-22
Captured: 2026-09-09T23:38:02.384588+00:00
Current indication reconciliation: Not reconciled

Boxed warning in this label

WARNING: CYTOKINE RELEASE SYNDROME AND IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Cytokine release syndrome (CRS), including serious or fatal reactions, can occur in patients receiving EPKINLY. Initiate treatment with the EPKINLY step-up dosage schedule to reduce the incidence and severity of CRS. Withhold EPKINLY until CRS resolves or permanently discontinue based on severity [see Dosage and Administration (2.1 , 2.2 , 2.6) and Warnings and Precautions (5.1) ] . Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), including life-threatening and fatal reactions, can occur with EPKINLY. Monitor patients for neurological signs or symptoms of ICANS during treatment. Withhold EPKINLY until ICANS resolves or permanently discontinue based on severity [see Dosage and Administration (2.1 , 2.2 , 2.6) and Warnings and Precautions (5.2) ] . WARNING: CYTOKINE RELEASE SYNDROME and IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME See full prescribing information for complete boxed warning. Cytokine release syndrome (CRS), including serious or fatal reactions, can occur in patients receiving EPKINLY. Initiate treatment with the EPKINLY step-up dosage schedule to reduce the incidence and severity of CRS. Withhold EPKINLY until CRS resolves or permanently discontinue based on severity. ( 2.1 , 2.2 , 2.6 , 5.1 ) Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), including life-threatening and fatal reactions, can occur with EPKINLY. Monitor patients for neurological signs or symptoms of ICANS during treatment. Withhold EPKINLY until ICANS resolves or permanently discontinue based on severity. ( 2.1 , 2.2 , 2.6 , 5.2 )

Indications and usage: exact source text

1 INDICATIONS AND USAGE EPKINLY is a bispecific CD20-directed CD3 T-cell engager indicated: For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. ( 1.1 ) This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). In combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). ( 1.2 ) As monotherapy for the treatment of adult patients with relapsed or refractory FL after two or more lines of systemic therapy. ( 1.2 ) 1.1 DLBCL and High-grade B-cell Lymphoma EPKINLY is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14.1) ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). 1.2 Follicular Lymphoma EPKINLY is indicated in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). EPKINLY is indicated as monotherapy for the treatment of adult patients with relapsed or refractory FL after two or more lines of systemic therapy.

Full extracted label fields

application numbers

BLA761324

boxed warning exact

WARNING: CYTOKINE RELEASE SYNDROME AND IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Cytokine release syndrome (CRS), including serious or fatal reactions, can occur in patients receiving EPKINLY. Initiate treatment with the EPKINLY step-up dosage schedule to reduce the incidence and severity of CRS. Withhold EPKINLY until CRS resolves or permanently discontinue based on severity [see Dosage and Administration (2.1 , 2.2 , 2.6) and Warnings and Precautions (5.1) ] . Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), including life-threatening and fatal reactions, can occur with EPKINLY. Monitor patients for neurological signs or symptoms of ICANS during treatment. Withhold EPKINLY until ICANS resolves or permanently discontinue based on severity [see Dosage and Administration (2.1 , 2.2 , 2.6) and Warnings and Precautions (5.2) ] . WARNING: CYTOKINE RELEASE SYNDROME and IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME See full prescribing information for complete boxed warning. Cytokine release syndrome (CRS), including serious or fatal reactions, can occur in patients receiving EPKINLY. Initiate treatment with the EPKINLY step-up dosage schedule to reduce the incidence and severity of CRS. Withhold EPKINLY until CRS resolves or permanently discontinue based on severity. ( 2.1 , 2.2 , 2.6 , 5.1 ) Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), including life-threatening and fatal reactions, can occur with EPKINLY. Monitor patients for neurological signs or symptoms of ICANS during treatment. Withhold EPKINLY until ICANS resolves or permanently discontinue based on severity. ( 2.1 , 2.2 , 2.6 , 5.2 )

brand names

EPKINLY

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d7836711-b677-412d-bf2d-0f7c8444103a

generic names

EPCORITAMAB-BYSP

e2f39a72-c677-4ded-a10c-da739f457180

indications and usage exact

1 INDICATIONS AND USAGE EPKINLY is a bispecific CD20-directed CD3 T-cell engager indicated: For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. ( 1.1 ) This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). In combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). ( 1.2 ) As monotherapy for the treatment of adult patients with relapsed or refractory FL after two or more lines of systemic therapy. ( 1.2 ) 1.1 DLBCL and High-grade B-cell Lymphoma EPKINLY is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14.1) ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). 1.2 Follicular Lymphoma EPKINLY is indicated in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). EPKINLY is indicated as monotherapy for the treatment of adult patients with relapsed or refractory FL after two or more lines of systemic therapy.

indications and usage tables exact

is original packager

true

manufacturer names

Genmab US, Inc.

matched search terms

lymphoma

package ndcs

82705-010-01
82705-002-01

product ndcs

82705-002
82705-010

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

Indications and Usage ( 1.2 ) 11/2025 Dosage and Administration ( 2.1 ) 3/2026 Dosage and Administration ( 2.2 , 2.5 , 2.6 ) 11/2025 Warnings and Precautions ( 5.1 ) 3/2026 Warnings and Precautions ( 5.2 , 5.4 ) 11/2025 Warnings and Precautions, Infections ( 5.3 ) 6/2026

record type

complete_spl_indications_section_candidate

routes

SUBCUTANEOUS

rxcuis

2637399
2637405
2637408
2637411

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00700.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

BLA761324

brand names

EPKINLY

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 543
end exclusive: true
exact text: 1 INDICATIONS AND USAGE EPKINLY is a bispecific CD20-directed CD3 T-cell engager indicated: For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. ( 1.1 ) This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and descri
label id: e2f39a72-c677-4ded-a10c-da739f457180
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start: 0

current approval status

not_reconciled

duplicate text group

dup-a8b2913b797e519c2596

extraction review status

automated_candidate_pending_source_review

generic names

EPCORITAMAB-BYSP

ind-span-d9a171c6475dc2876a0e

label id

e2f39a72-c677-4ded-a10c-da739f457180

positive predicate support span

end: 90
end exclusive: true
exact text: is a bispecific CD20-directed CD3 T-cell engager indicated
label id: e2f39a72-c677-4ded-a10c-da739f457180
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start: 32

qualifier mentions

context exact
directed CD3 T-cell engager indicated: For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (
kind
age
polarity
not_inferred
span
end
127
end exclusive
true
exact text
adult patients
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
113
context exact
1 INDICATIONS AND USAGE EPKINLY is a bispecific CD20-directed CD3 T-cell engager indicated: For the treatment of adult patients with relapsed or refract
kind
biomarker
polarity
not_inferred
span
end
92
end exclusive
true
exact text
CD20-directed CD3 T-cell engager indicated:
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
48
context exact
engager indicated: For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL
kind
stage_or_setting
polarity
not_inferred
span
end
176
end exclusive
true
exact text
relapsed or refractory diffuse large B-cell
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
133

regulatory links

candidate source span
end
343
end exclusive
true
exact text
1 INDICATIONS AND USAGE EPKINLY is a bispecific CD20-directed CD3 T-cell engager indicated: For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy.
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
0
fda indication exact
Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy.
fda source row index
31
fda source sha256
8df28be8da28c19a2d63f9c7ada45adf8aa0a5f11be1a2b4df67ce8eea572def
fda status record id
fda-aa-54f8004f5a784e287b01
interpretation
Source wording correspondence to a dated FDA status row; current approval not certified
match method
whole_indication_literal_normalized_substring
matching review status
source_comparison_only_clinical_review_pending
scope relationship
whole_fda_indication_text_present
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals
status category
ongoing
status event date
2023-05-19
supporting anchor spans

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

abbreviation
FL
definition exact
follicular lymphoma
definition span
end
732
end exclusive
true
exact text
follicular lymphoma (FL)
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
708
abbreviation
DLBCL
definition exact
diffuse large B-cell lymphoma
definition span
end
193
end exclusive
true
exact text
diffuse large B-cell lymphoma (DLBCL)
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
156

source span

end: 343
end exclusive: true
exact text: 1 INDICATIONS AND USAGE EPKINLY is a bispecific CD20-directed CD3 T-cell engager indicated: For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy.
label id: e2f39a72-c677-4ded-a10c-da739f457180
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e2f39a72-c677-4ded-a10c-da739f457180%22

spl effective date

2026-06-22

spl set id

d7836711-b677-412d-bf2d-0f7c8444103a

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Read indication-specific status → · whole_fda_indication_text_present

Passage 2 · approval contingency

application numbers

BLA761324

brand names

EPKINLY

classification reasons

approval_contingency_words

clinical review status

pending

content role

approval_contingency

context span

end: 657
end exclusive: true
exact text: refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. ( 1.1 ) This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). In combination with lenalidomide and rituximab for the treat
label id: e2f39a72-c677-4ded-a10c-da739f457180
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start: 144

current approval status

not_reconciled

duplicate text group

dup-d5352da35e879c5674f3

extraction review status

automated_candidate_pending_source_review

generic names

EPCORITAMAB-BYSP

ind-span-ebf329342c17ce5ac6b3

label id

e2f39a72-c677-4ded-a10c-da739f457180

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

abbreviation
FL
definition exact
follicular lymphoma
definition span
end
732
end exclusive
true
exact text
follicular lymphoma (FL)
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
708
abbreviation
DLBCL
definition exact
diffuse large B-cell lymphoma
definition span
end
193
end exclusive
true
exact text
diffuse large B-cell lymphoma (DLBCL)
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
156

source span

end: 457
end exclusive: true
exact text: ( 1.1 ) This indication is approved under accelerated approval based on response rate and durability of response.
label id: e2f39a72-c677-4ded-a10c-da739f457180
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start: 344

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e2f39a72-c677-4ded-a10c-da739f457180%22

spl effective date

2026-06-22

spl set id

d7836711-b677-412d-bf2d-0f7c8444103a

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 3 · approval contingency

application numbers

BLA761324

brand names

EPKINLY

classification reasons

approval_contingency_words

clinical review status

pending

content role

approval_contingency

context span

end: 796
end exclusive: true
exact text: lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. ( 1.1 ) This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). In combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). ( 1.2 ) As monotherapy for the treatment of adult patients wit
label id: e2f39a72-c677-4ded-a10c-da739f457180
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start: 258

current approval status

not_reconciled

duplicate text group

dup-5dd65fa8811c664c3dcb

extraction review status

automated_candidate_pending_source_review

generic names

EPCORITAMAB-BYSP

ind-span-1382a374bf38caee55a2

label id

e2f39a72-c677-4ded-a10c-da739f457180

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

abbreviation
FL
definition exact
follicular lymphoma
definition span
end
732
end exclusive
true
exact text
follicular lymphoma (FL)
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
708
abbreviation
DLBCL
definition exact
diffuse large B-cell lymphoma
definition span
end
193
end exclusive
true
exact text
diffuse large B-cell lymphoma (DLBCL)
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
156

source span

end: 596
end exclusive: true
exact text: Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
label id: e2f39a72-c677-4ded-a10c-da739f457180
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start: 458

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e2f39a72-c677-4ded-a10c-da739f457180%22

spl effective date

2026-06-22

spl set id

d7836711-b677-412d-bf2d-0f7c8444103a

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 4 · unclassified context

application numbers

BLA761324

brand names

EPKINLY

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 933
end exclusive: true
exact text: approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). In combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). ( 1.2 ) As monotherapy for the treatment of adult patients with relapsed or refractory FL after two or more lines of systemic therapy. ( 1.2 ) 1.1 DLBCL and High-grade B-cell Lymphoma EPKINLY is indi
label id: e2f39a72-c677-4ded-a10c-da739f457180
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start: 397

current approval status

not_reconciled

duplicate text group

dup-9a5715cfe8e752c4a7e0

extraction review status

automated_candidate_pending_source_review

generic names

EPCORITAMAB-BYSP

ind-span-efce785479328b0a0ddc

label id

e2f39a72-c677-4ded-a10c-da739f457180

positive predicate support span

Source null

qualifier mentions

context exact
nation with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL).
kind
age
polarity
not_inferred
span
end
679
end exclusive
true
exact text
adult patients
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
665
context exact
mide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL).
kind
stage_or_setting
polarity
not_inferred
span
end
728
end exclusive
true
exact text
relapsed or refractory follicular lymphoma
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
685
context exact
In combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL).
kind
regimen
polarity
not_inferred
span
end
732
end exclusive
true
exact text
In combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL)
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
597

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

abbreviation
FL
definition exact
follicular lymphoma
definition span
end
732
end exclusive
true
exact text
follicular lymphoma (FL)
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
708
abbreviation
DLBCL
definition exact
diffuse large B-cell lymphoma
definition span
end
193
end exclusive
true
exact text
diffuse large B-cell lymphoma (DLBCL)
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
156

source span

end: 733
end exclusive: true
exact text: In combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL).
label id: e2f39a72-c677-4ded-a10c-da739f457180
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start: 597

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e2f39a72-c677-4ded-a10c-da739f457180%22

spl effective date

2026-06-22

spl set id

d7836711-b677-412d-bf2d-0f7c8444103a

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 5 · unclassified context

application numbers

BLA761324

brand names

EPKINLY

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 941
end exclusive: true
exact text: nd description of clinical benefit in a confirmatory trial(s). In combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). ( 1.2 ) As monotherapy for the treatment of adult patients with relapsed or refractory FL after two or more lines of systemic therapy. ( 1.2 ) 1.1 DLBCL and High-grade B-cell Lymphoma EPKINLY is indicated fo
label id: e2f39a72-c677-4ded-a10c-da739f457180
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start: 534

current approval status

not_reconciled

duplicate text group

dup-66164ea7f68436b19857

extraction review status

automated_candidate_pending_source_review

generic names

EPCORITAMAB-BYSP

ind-span-7eed13980f0523df80a8

label id

e2f39a72-c677-4ded-a10c-da739f457180

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

abbreviation
FL
definition exact
follicular lymphoma
definition span
end
732
end exclusive
true
exact text
follicular lymphoma (FL)
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
708
abbreviation
DLBCL
definition exact
diffuse large B-cell lymphoma
definition span
end
193
end exclusive
true
exact text
diffuse large B-cell lymphoma (DLBCL)
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
156

source span

end: 741
end exclusive: true
exact text: ( 1.2 )
label id: e2f39a72-c677-4ded-a10c-da739f457180
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start: 734

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e2f39a72-c677-4ded-a10c-da739f457180%22

spl effective date

2026-06-22

spl set id

d7836711-b677-412d-bf2d-0f7c8444103a

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 6 · unclassified context

application numbers

BLA761324

brand names

EPKINLY

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1068
end exclusive: true
exact text: iption of clinical benefit in a confirmatory trial(s). In combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). ( 1.2 ) As monotherapy for the treatment of adult patients with relapsed or refractory FL after two or more lines of systemic therapy. ( 1.2 ) 1.1 DLBCL and High-grade B-cell Lymphoma EPKINLY is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, i
label id: e2f39a72-c677-4ded-a10c-da739f457180
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start: 542

current approval status

not_reconciled

duplicate text group

dup-5fa8798be31b3bc33626

extraction review status

automated_candidate_pending_source_review

generic names

EPCORITAMAB-BYSP

ind-span-1e81c42191e4e2591fda

label id

e2f39a72-c677-4ded-a10c-da739f457180

positive predicate support span

Source null

qualifier mentions

context exact
As monotherapy for the treatment of adult patients with relapsed or refractory FL after two or more lines of s
kind
age
polarity
not_inferred
span
end
792
end exclusive
true
exact text
adult patients
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
778
context exact
As monotherapy for the treatment of adult patients with relapsed or refractory FL after two or more lines of systemic therapy.
kind
stage_or_setting
polarity
not_inferred
span
end
841
end exclusive
true
exact text
relapsed or refractory FL after two or more
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
798
context exact
As monotherapy for the treatment of adult patients with relapsed or refractory FL after two or more lines of systemic therapy.
kind
regimen
polarity
not_inferred
span
end
867
end exclusive
true
exact text
As monotherapy for the treatment of adult patients with relapsed or refractory FL after two or more lines of systemic therapy
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
742

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

abbreviation
FL
definition exact
follicular lymphoma
definition span
end
732
end exclusive
true
exact text
follicular lymphoma (FL)
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
708
abbreviation
DLBCL
definition exact
diffuse large B-cell lymphoma
definition span
end
193
end exclusive
true
exact text
diffuse large B-cell lymphoma (DLBCL)
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
156

source span

end: 868
end exclusive: true
exact text: As monotherapy for the treatment of adult patients with relapsed or refractory FL after two or more lines of systemic therapy.
label id: e2f39a72-c677-4ded-a10c-da739f457180
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start: 742

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e2f39a72-c677-4ded-a10c-da739f457180%22

spl effective date

2026-06-22

spl set id

d7836711-b677-412d-bf2d-0f7c8444103a

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 7 · unclassified context

application numbers

BLA761324

brand names

EPKINLY

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1076
end exclusive: true
exact text: t patients with relapsed or refractory follicular lymphoma (FL). ( 1.2 ) As monotherapy for the treatment of adult patients with relapsed or refractory FL after two or more lines of systemic therapy. ( 1.2 ) 1.1 DLBCL and High-grade B-cell Lymphoma EPKINLY is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including
label id: e2f39a72-c677-4ded-a10c-da739f457180
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start: 669

current approval status

not_reconciled

duplicate text group

dup-66164ea7f68436b19857

extraction review status

automated_candidate_pending_source_review

generic names

EPCORITAMAB-BYSP

ind-span-d1ee792797a37e745d38

label id

e2f39a72-c677-4ded-a10c-da739f457180

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

abbreviation
FL
definition exact
follicular lymphoma
definition span
end
732
end exclusive
true
exact text
follicular lymphoma (FL)
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
708
abbreviation
DLBCL
definition exact
diffuse large B-cell lymphoma
definition span
end
193
end exclusive
true
exact text
diffuse large B-cell lymphoma (DLBCL)
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
156

source span

end: 876
end exclusive: true
exact text: ( 1.2 )
label id: e2f39a72-c677-4ded-a10c-da739f457180
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start: 869

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e2f39a72-c677-4ded-a10c-da739f457180%22

spl effective date

2026-06-22

spl set id

d7836711-b677-412d-bf2d-0f7c8444103a

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · positive indication candidate

application numbers

BLA761324

brand names

EPKINLY

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1390
end exclusive: true
exact text: ts with relapsed or refractory follicular lymphoma (FL). ( 1.2 ) As monotherapy for the treatment of adult patients with relapsed or refractory FL after two or more lines of systemic therapy. ( 1.2 ) 1.1 DLBCL and High-grade B-cell Lymphoma EPKINLY is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14.1) ]. Continued approval for this indication may be contingent upon
label id: e2f39a72-c677-4ded-a10c-da739f457180
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start: 677

current approval status

not_reconciled

duplicate text group

dup-186288f740f612e201be

extraction review status

automated_candidate_pending_source_review

generic names

EPCORITAMAB-BYSP

ind-span-d08a783e1aa9f6b087c1

label id

e2f39a72-c677-4ded-a10c-da739f457180

positive predicate support span

end: 938
end exclusive: true
exact text: is indicated
label id: e2f39a72-c677-4ded-a10c-da739f457180
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start: 926

qualifier mentions

context exact
e B-cell Lymphoma EPKINLY is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (
kind
age
polarity
not_inferred
span
end
974
end exclusive
true
exact text
adult patients
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
960
context exact
KINLY is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL
kind
stage_or_setting
polarity
not_inferred
span
end
1023
end exclusive
true
exact text
relapsed or refractory diffuse large B-cell
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
980

regulatory links

candidate source span
end
1190
end exclusive
true
exact text
1.1 DLBCL and High-grade B-cell Lymphoma EPKINLY is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy.
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
877
fda indication exact
Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy.
fda source row index
31
fda source sha256
8df28be8da28c19a2d63f9c7ada45adf8aa0a5f11be1a2b4df67ce8eea572def
fda status record id
fda-aa-54f8004f5a784e287b01
interpretation
Source wording correspondence to a dated FDA status row; current approval not certified
match method
whole_indication_literal_normalized_substring
matching review status
source_comparison_only_clinical_review_pending
scope relationship
whole_fda_indication_text_present
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals
status category
ongoing
status event date
2023-05-19
supporting anchor spans

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

abbreviation
FL
definition exact
follicular lymphoma
definition span
end
732
end exclusive
true
exact text
follicular lymphoma (FL)
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
708
abbreviation
DLBCL
definition exact
diffuse large B-cell lymphoma
definition span
end
193
end exclusive
true
exact text
diffuse large B-cell lymphoma (DLBCL)
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
156

source span

end: 1190
end exclusive: true
exact text: 1.1 DLBCL and High-grade B-cell Lymphoma EPKINLY is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy.
label id: e2f39a72-c677-4ded-a10c-da739f457180
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start: 877

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e2f39a72-c677-4ded-a10c-da739f457180%22

spl effective date

2026-06-22

spl set id

d7836711-b677-412d-bf2d-0f7c8444103a

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Read indication-specific status → · whole_fda_indication_text_present

Passage 9 · approval contingency

application numbers

BLA761324

brand names

EPKINLY

classification reasons

approval_contingency_words

clinical review status

pending

content role

approval_contingency

context span

end: 1527
end exclusive: true
exact text: refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14.1) ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). 1.2 Follicular Lymphoma EPKINLY is indicated in combination
label id: e2f39a72-c677-4ded-a10c-da739f457180
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start: 991

current approval status

not_reconciled

duplicate text group

dup-42605b7f3927e3183fca

extraction review status

automated_candidate_pending_source_review

generic names

EPCORITAMAB-BYSP

ind-span-409ae547a0572005aa65

label id

e2f39a72-c677-4ded-a10c-da739f457180

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

abbreviation
FL
definition exact
follicular lymphoma
definition span
end
732
end exclusive
true
exact text
follicular lymphoma (FL)
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
708
abbreviation
DLBCL
definition exact
diffuse large B-cell lymphoma
definition span
end
193
end exclusive
true
exact text
diffuse large B-cell lymphoma (DLBCL)
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
156

source span

end: 1327
end exclusive: true
exact text: This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14.1) ].
label id: e2f39a72-c677-4ded-a10c-da739f457180
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start: 1191

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e2f39a72-c677-4ded-a10c-da739f457180%22

spl effective date

2026-06-22

spl set id

d7836711-b677-412d-bf2d-0f7c8444103a

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 10 · approval contingency

application numbers

BLA761324

brand names

EPKINLY

classification reasons

approval_contingency_words

clinical review status

pending

content role

approval_contingency

context span

end: 1666
end exclusive: true
exact text: e B-cell lymphoma after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14.1) ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). 1.2 Follicular Lymphoma EPKINLY is indicated in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). EPKINLY is indica
label id: e2f39a72-c677-4ded-a10c-da739f457180
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start: 1128

current approval status

not_reconciled

duplicate text group

dup-5dd65fa8811c664c3dcb

extraction review status

automated_candidate_pending_source_review

generic names

EPCORITAMAB-BYSP

ind-span-faa402e71b869896a381

label id

e2f39a72-c677-4ded-a10c-da739f457180

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

abbreviation
FL
definition exact
follicular lymphoma
definition span
end
732
end exclusive
true
exact text
follicular lymphoma (FL)
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
708
abbreviation
DLBCL
definition exact
diffuse large B-cell lymphoma
definition span
end
193
end exclusive
true
exact text
diffuse large B-cell lymphoma (DLBCL)
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
156

source span

end: 1466
end exclusive: true
exact text: Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
label id: e2f39a72-c677-4ded-a10c-da739f457180
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start: 1328

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e2f39a72-c677-4ded-a10c-da739f457180%22

spl effective date

2026-06-22

spl set id

d7836711-b677-412d-bf2d-0f7c8444103a

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 11 · positive indication candidate

application numbers

BLA761324

brand names

EPKINLY

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1796
end exclusive: true
exact text: e and durability of response [see Clinical Studies (14.1) ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). 1.2 Follicular Lymphoma EPKINLY is indicated in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). EPKINLY is indicated as monotherapy for the treatment of adult patients with relapsed or refractory FL after two or more lines of systemic therapy.
label id: e2f39a72-c677-4ded-a10c-da739f457180
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start: 1267

current approval status

not_reconciled

duplicate text group

dup-be229e102baf47afd94c

extraction review status

automated_candidate_pending_source_review

generic names

EPCORITAMAB-BYSP

ind-span-749195b1b70df883c9a1

label id

e2f39a72-c677-4ded-a10c-da739f457180

positive predicate support span

end: 1511
end exclusive: true
exact text: is indicated
label id: e2f39a72-c677-4ded-a10c-da739f457180
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start: 1499

qualifier mentions

context exact
nation with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL).
kind
age
polarity
not_inferred
span
end
1594
end exclusive
true
exact text
adult patients
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
1580
context exact
mide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL).
kind
stage_or_setting
polarity
not_inferred
span
end
1643
end exclusive
true
exact text
relapsed or refractory follicular lymphoma
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
1600
context exact
1.2 Follicular Lymphoma EPKINLY is indicated in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL).
kind
regimen
polarity
not_inferred
span
end
1647
end exclusive
true
exact text
in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL)
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
1512

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

abbreviation
FL
definition exact
follicular lymphoma
definition span
end
732
end exclusive
true
exact text
follicular lymphoma (FL)
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
708
abbreviation
DLBCL
definition exact
diffuse large B-cell lymphoma
definition span
end
193
end exclusive
true
exact text
diffuse large B-cell lymphoma (DLBCL)
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
156

source span

end: 1648
end exclusive: true
exact text: 1.2 Follicular Lymphoma EPKINLY is indicated in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL).
label id: e2f39a72-c677-4ded-a10c-da739f457180
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start: 1467

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e2f39a72-c677-4ded-a10c-da739f457180%22

spl effective date

2026-06-22

spl set id

d7836711-b677-412d-bf2d-0f7c8444103a

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 12 · positive indication candidate

application numbers

BLA761324

brand names

EPKINLY

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement
source_defined_disease_abbreviation

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1796
end exclusive: true
exact text: rmatory trial(s). 1.2 Follicular Lymphoma EPKINLY is indicated in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). EPKINLY is indicated as monotherapy for the treatment of adult patients with relapsed or refractory FL after two or more lines of systemic therapy.
label id: e2f39a72-c677-4ded-a10c-da739f457180
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start: 1449

current approval status

not_reconciled

duplicate text group

dup-1d7ddc55f9aded2a7b09

extraction review status

automated_candidate_pending_source_review

generic names

EPCORITAMAB-BYSP

ind-span-314b6d373de11b65def4

label id

e2f39a72-c677-4ded-a10c-da739f457180

positive predicate support span

end: 1669
end exclusive: true
exact text: is indicated
label id: e2f39a72-c677-4ded-a10c-da739f457180
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start: 1657

qualifier mentions

context exact
EPKINLY is indicated as monotherapy for the treatment of adult patients with relapsed or refractory FL after two or more lines of s
kind
age
polarity
not_inferred
span
end
1720
end exclusive
true
exact text
adult patients
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
1706
context exact
ted as monotherapy for the treatment of adult patients with relapsed or refractory FL after two or more lines of systemic therapy.
kind
stage_or_setting
polarity
not_inferred
span
end
1769
end exclusive
true
exact text
relapsed or refractory FL after two or more
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
1726
context exact
EPKINLY is indicated as monotherapy for the treatment of adult patients with relapsed or refractory FL after two or more lines of systemic therapy.
kind
regimen
polarity
not_inferred
span
end
1795
end exclusive
true
exact text
as monotherapy for the treatment of adult patients with relapsed or refractory FL after two or more lines of systemic therapy
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
1670

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

abbreviation
FL
definition exact
follicular lymphoma
definition span
end
732
end exclusive
true
exact text
follicular lymphoma (FL)
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
708
abbreviation
DLBCL
definition exact
diffuse large B-cell lymphoma
definition span
end
193
end exclusive
true
exact text
diffuse large B-cell lymphoma (DLBCL)
label id
e2f39a72-c677-4ded-a10c-da739f457180
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start
156

source span

end: 1796
end exclusive: true
exact text: EPKINLY is indicated as monotherapy for the treatment of adult patients with relapsed or refractory FL after two or more lines of systemic therapy.
label id: e2f39a72-c677-4ded-a10c-da739f457180
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: effec78d5709b278e74da8e1d842442ee08b203282ff937213c7bdb0a19359a1
start: 1649

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e2f39a72-c677-4ded-a10c-da739f457180%22

spl effective date

2026-06-22

spl set id

d7836711-b677-412d-bf2d-0f7c8444103a

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Preserved source evidence · Not medical advice